A study reveals significant genomic differences in metastatic prostate cancer among veterans, highlighting the need for ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Combination therapy with savolitinib and osimertinib shows promising results in treating advanced NSCLC with EGFR mutations ...

Daratumumab effectively delays multiple myeloma relapse by monitoring minimal residual disease, offering hope for improved ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Premal Thaker, MD, MS, discusses important implications and takeaways of the phase 1/2 OVATION study of IMMN-1 in addition to chemotherapy for the treatment of newly diagnosed epithelial ovarian ...

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy caregiver challenges and referral ...

During a live event, Neal E. Ready, MD, and participants discussed use of PD-L1 status in non–small cell lung cancer and ...

The IsKia trial reveals that isatuximab enhances MRD negativity in newly diagnosed multiple myeloma, especially in high-risk ...

Erika Hamilton, MD, discusses the mechanism of action of emiltatug ledadotin, a B7-H4-directed Dolasynthen antibody-drug conjugate.

SENTI-202, a groundbreaking CAR NK-cell therapy, targets relapsed/refractory AML, offering hope for patients with limited ...